Answers are grounded in this paper and cite their sources.
Background: The optimal axillary restaging strategy for ipsilateral breast tumour recurrence (IBTR) remains uncertain. Repeat sentinel lymph node biopsy (rSLNB) may provide nodal information while avoiding routine axillary lymph node dissection (ALND). This systematic review and meta-analysis evaluated the technical feasibility, lymphatic drainage, nodal positivity, diagnostic performance and regional safety of rSLNB in patients with IBTR. Methods: PubMed/MEDLINE, Europe PMC, ClinicalTrials.gov and WHO ICTRP records were searched according to PRISMA 2020. Overlapping populations were reconciled to retain independent cohorts. Proportions were pooled with random-effects logit models (restricted maximum likelihood, Hartung–Knapp adjustment), and 95% prediction intervals were calculated; sources of heterogeneity were explored by meta-regression. Risk of bias was appraised with Joanna Briggs Institute checklists and certainty of evidence with GRADE. Results: Eighteen independent cohorts comprising 1718 attempted procedures were included. The pooled successful identification/harvest rate was 68.0% (95% CI 60.1–74.9%), with substantial heterogeneity (I2 = 81.1%) and a 95% prediction interval of 38.8–87.6%, indicating that the success rate in an individual centre may differ considerably from the pooled estimate. A higher proportion of patients with previous ALND was associated with lower success in exploratory meta-regression. In exploratory subgroup analyses based on two and four cohorts, identification was 80.8% after previous SLNB and 59.0% after previous ALND. Aberrant drainage was frequent but highly variable (32.9%; 95% prediction interval 2.4–90.9%). The repeat sentinel node was positive in 15.1% (95% CI 12.0–18.7%) of successfully staged patients, corresponding to roughly one in ten attempted procedures. The pooled negative predictive value was 93.3% (four cohorts), and regional recurrence after a tumour-negative rSLNB occurred in 9 of 201 patients (4.5%). The certainty of evidence was low for nodal positivity and very low for all other outcomes. Conclusions: rSLNB achieves nodal restaging in about two-thirds of patients with IBTR and detects nodal metastases in about one in ten attempted procedures, but its success varies widely between settings and its prognostic value remains uncertain. It should be offered selectively, when nodal status is expected to change management, rather than as a universally applicable standard.
No takes yet. Share an insight, caveat, or question.
Faur et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: